Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2013 1
2014 1
2016 1
2017 1
2020 2
2021 1
2022 2
2023 3
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Primary Sjögren's syndrome: Extraglandular manifestations and hydroxychloroquine therapy.
Demarchi J, Papasidero S, Medina MA, Klajn D, Chaparro Del Moral R, Rillo O, Martiré V, Crespo G, Secco A, Catalan Pellet A, Amitrano C, Crow C, Asnal C, Pucci P, Caeiro F, Benzanquen N, Pirola JP, Mayer M, Zazzetti F, Velez S, Barreira J, Tamborenea N, Santiago L, Raiti L. Demarchi J, et al. Among authors: zazzetti f. Clin Rheumatol. 2017 Nov;36(11):2455-2460. doi: 10.1007/s10067-017-3822-3. Epub 2017 Sep 14. Clin Rheumatol. 2017. PMID: 28913747
Predictors of first hospitalization due to disease activity and infections in systemic lupus erythematosus patients.
Pons-Estel GJ, Quintana R, Ugarte-Gil MF, Harvey GB, Wojdyla D, Serrano-Morales R, Gómez Puerta JA, García MA, Catoggio LJ, Saurit V, Drenkard C, Da Silva NA, Cavalcanti F, Borba E, Sato E, Neira O, Massardo L, Vásquez G, Gonzalez LA, Guibert-Toledano M, Silveira LH, García De La Torre I, Sauza Del Pozo MJ, Chacón R, Cardiel MH, Orillion A, Sbarigia U, Alemao E, Zazzetti F, Alarcón GS, Pons-Estel BA. Pons-Estel GJ, et al. Among authors: zazzetti f. Lupus. 2024 Nov;33(13):1492-1501. doi: 10.1177/09612033241283551. Epub 2024 Sep 11. Lupus. 2024. PMID: 39259025 Free PMC article.
LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort.
Ugarte-Gil MF, Gamboa-Cardenas RV, Reátegui-Sokolova C, Pimentel-Quiroz VR, Medina M, Elera-Fitzcarrald C, Zevallos F, Pastor-Asurza CA, Lofland J, Zazzetti F, Karyekar CS, Alarcón GS, Perich-Campos RA. Ugarte-Gil MF, et al. Among authors: zazzetti f. Lupus Sci Med. 2022 Feb;9(1):e000616. doi: 10.1136/lupus-2021-000616. Lupus Sci Med. 2022. PMID: 35193948 Free PMC article.
Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort.
Ugarte-Gil MF, Gamboa-Cardenas RV, Reátegui-Sokolova C, Pimentel-Quiroz VR, Medina M, Elera-Fitzcarrald C, Zevallos F, Pastor-Asurza CA, Zazzetti F, Karyekar CS, Alarcón GS, Perich-Campos RA. Ugarte-Gil MF, et al. Among authors: zazzetti f. Lupus Sci Med. 2022 Mar;9(1):e000641. doi: 10.1136/lupus-2021-000641. Lupus Sci Med. 2022. PMID: 35351811 Free PMC article.
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
Ritchlin CT, Helliwell PS, Boehncke WH, Soriano ER, Hsia EC, Kollmeier AP, Chakravarty SD, Zazzetti F, Subramanian RA, Xu XL, Zuraw QC, Sheng S, Jiang Y, Agarwal P, Zhou B, Zhuang Y, Shawi M, Karyekar CS, Deodhar A. Ritchlin CT, et al. Among authors: zazzetti f. RMD Open. 2021 Feb;7(1):e001457. doi: 10.1136/rmdopen-2020-001457. RMD Open. 2021. PMID: 33568556 Free PMC article. Clinical Trial.
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.
Ritchlin CT, Deodhar A, Boehncke WH, Soriano ER, Kollmeier AP, Xu XL, Zazzetti F, Shawi M, Jiang Y, Sheng S, Helliwell PS. Ritchlin CT, et al. Among authors: zazzetti f. ACR Open Rheumatol. 2023 Mar;5(3):149-164. doi: 10.1002/acr2.11523. Epub 2023 Feb 10. ACR Open Rheumatol. 2023. PMID: 36762512 Free PMC article.
15 results